FDA alerts patients and health care professionals about clinical trial results showing an increased risk of death associated with Pepaxto (melphalan flufenamide)

FDA alerts patients and health care professionals that a clinical trial evaluating Pepaxto (melphalan flufenamide) showed an increased risk of death.

Source: FDA Center for Drug Evaluation and Research - What's New - July 28, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news